We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

SRE:NYSEDBA Sempra Analysis

Data as of 2026-06-18 - not real-time

$90.25

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

Sempra (SRE) trades at $90.25, just below its 20‑day SMA of 90.72 and 200‑day SMA of 90.98, indicating modest short‑term weakness despite a neutral RSI of 45.6. The MACD histogram is positive and the signal line is bullish, suggesting underlying momentum could reverse lower pressure. Valuation metrics are mixed: a trailing P/E of 30.7 far exceeds the industry average of 20.5, while the DCF‑derived fair value of $15 signals deep overvaluation, yet the forward P/E of 16.3 and analyst consensus target of $103.5 imply a ~14% upside. The stock offers a 2.87% dividend yield, but an 88% payout ratio combined with a –$28.2 B free‑cash‑flow gap raises sustainability concerns.
Fundamentally, revenue has contracted 3.9% YoY and the balance sheet carries $36.4 B of debt against $0.8 B of cash, yielding a high debt‑to‑equity of 85%. However, operating margins remain strong at 30.6% and forward EPS is projected to double, driven in part by the newly‑serviceable Port Arthur Pipeline Louisiana Connector project. Activist investor Voss Capital’s call to spin off the Oncor unit adds a potential catalyst that could unlock value or introduce restructuring risk. The utility sector’s regulated nature provides a defensive backdrop, yet regulatory changes in California and Texas could impact rate structures. Overall, low beta (0.27) and stable volume temper market volatility, but the combination of leverage, dividend strain, and valuation gaps warrants a cautious stance.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • price near support
  • high valuation relative to peers
  • dividend sustainability concerns

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • pipeline project revenue lift
  • forward earnings growth
  • analyst upside to target

Long Term

> 3 years
Neutral
Model confidence: 7/10

Key Factors

  • high leverage and negative free cash flow
  • potential Oncor spin‑off
  • regulated cash‑flow stability

Key Metrics & Analysis

Financial Health

Revenue Growth-3.90%
Profit Margin14.43%
P/E Ratio30.7
ROE5.69%
ROA1.81%
Debt/Equity85.27
P/B Ratio1.9
Op. Cash Flow$4.9B
Free Cash Flow$-28243374080
Industry P/E20.5

Technical Analysis

TrendNeutral
RSI45.6
Support$87.10
Resistance$93.36
MA 20$90.72
MA 50$92.63
MA 200$90.98
MACDBullish
VolumeStable
Fear & Greed Index90.88

Valuation

Fair Value$15.01
Target Price$103.50
Upside/Downside14.68%
GradeOvervalued
TypeBlend
Dividend Yield2.87%

Risk Assessment

Beta0.27
Volatility22.47%
Sector RiskLow
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.